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The optimal management of peritoneal carcinoma-
tosis of colorectal origin remains a challenging clini-
cal problem characterized by more questions than
answers. In recent years there has been a great
expansion of therapeutic options for patients with
metastatic colorectal cancer. Newer and more eﬀec-
tive systemic chemotherapeutic agents (e.g., oxalipl-
atin and irinotecan), targeted biologic therapies (e.g.,
bevacizumab, cetuximab, panitumumab) and ad-
vances in surgical indications for resection of visceral
metastases have greatly improved survival outcomes.
However, for the more than 15% of patients with
colorectal cancer who develop peritoneal metastases,
data to guide their therapy are limited, often resulting
in treatment decisions based upon strong patient and
provider convictions rather than established experi-
mental evidence.
Fortunately, signiﬁcant eﬀorts to improve the poor
prognosis for these patients are ongoing. One of the
most notable eﬀorts is increased use of the combi-
nation treatment of cytoreductive surgery (CS) with
perioperative (intra- or postoperative) intraperitoneal
chemotherapy (PIC) with or without hyperthermia.
Using this approach, single-center reports have noted
5-year survival rates of 20% to over 40% for patients
treated with CS and hyperthermic intraperitoneal
chemotherapy (HIPEC)—twice the expected survival
with systemic 5-ﬂuorouracil chemotherapy alone.1–3
Consequently, these and other data have led to a
recent consensus statement advocating the use of CS
and PIC in patients with peritoneal carcinomatosis
from colorectal cancer.4
In this issue Franko and colleagues report a ret-
rospective analysis of prospectively collected data
from their single-institutional experience regarding
multivisceral resection (MVR) during the course of
CS and HIPEC for colorectal peritoneal carcinoma-
tosis (n = 65).5 The purpose of their study was to
evaluate the impact of MVR during CS and HIPEC
on morbidity and survival outcomes. The overall
morbidity rate in this study was 60%. The perfor-
mance of a bowel anastomosis was an important
identiﬁed risk factor of signiﬁcant increase in mor-
bidity (70% with anastomosis versus 33% without,
P = 0.003) including increased rates of reoperation,
wound complications, enterocutaneous ﬁstulae, and
prolonged ileus. MVR, deﬁned as the resection of two
or more organs beyond peritonectomy and omen-
tectomy, was performed in 35 of 65 patients (54%).
MVR was not associated with signiﬁcant diﬀerences
in perioperative morbidity or mortality compared
with patients who did not require MVR during CS.
Additionally, patients who underwent complete or
nearly complete cytoreduction (deﬁned as residual
tumor implants <5 mm) had signiﬁcantly better
median survival after CS and HIPEC compared with
patients who had an incomplete cytoreduction (20.2
versus 10.6 months, P< 0.001) The performance of
MVR did not aﬀect median survival after CS and
HIPEC—neither from the time of diagnosis of stage
IV disease nor from the time of CS and HIPEC.
At least two important messages are highlighted by
the authors’ ﬁndings. Firstly, peritoneal cytoreduc-
tion with HIPEC is a potentially eﬀective modality
for selected patients with colorectal-cancer-associated
peritoneal carcinomatosis. Secondly, the key to
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maximizing survival outcomes is the achievement of a
complete cytoreduction, even when requiring MVR,
analogous to strategies for management of metastases
to other sites.
However, the data presented in this article also
highlight a number of unresolved issues regarding the
role of CS and HIPEC in the management of colo-
rectal peritoneal carcinomatosis. Cytoreductive sur-
gery and HIPEC are associated with high morbidity
(60% in this study and 23–44% in a number of other
studies), making optimal patient selection one of the
most important unresolved issues.2,6–10 Although a
novel ﬁnding of this study was the negative survival
impact of the presence of carcinomatosis on com-
puted tomography (CT) scan, further elaboration as
to how patients without radiographic evidence were
identiﬁed for CS and HIPEC would aid in patient
selection. It is reasonable to assume that identifying
patients earlier (i.e., with less tumor burden) could
lower the extent and morbidity of CS and HIPEC,
increase the rate of complete cytoreduction, and im-
prove the survival beneﬁt.
Another unresolved issue is the deﬁnition of an
optimal cytoreduction—how much is enough? In
their analysis the authors used a residual implant size
cutoﬀ of 5 mm while others have used 2.5 mm.4,11 It
is likely that the optimal level will be inﬂuenced by a
variety of factors such as tumor burden, disease dis-
tribution, prior surgical history, tumor biology, and
the type of intraperitoneal chemotherapy used—all
areas which require further investigation.
Perhaps the most important unanswered question
highlighted by this and all other studies of CS and
HIPEC to date is the extent to which each of the
components of treatment (e.g., cytoreduction or
intraperitoneal chemotherapy) improves outcomes
over modern multi-agent systemic therapies. Unfor-
tunately, answering this question is more complicated
than simply comparing survival outcomes after CS
and HIPEC with best systemic therapy. Given the
relatively high risk of morbidity and mortality asso-
ciated with CS and HIPEC, any potential advantage
needs to be measured in terms of both survival beneﬁt
and treatment toxicity. In addition, because CS and
HIPEC combine two treatment modalities, the eﬀects
of each modality (both beneﬁt and harm) must be
separately examined.
Undeniably, one of the most predictive factors for
survival among patients undergoing CS and HIPEC
for peritoneal carcinomatosis is completeness of
cytoreduction. Franko et al. have clearly demon-
strated that complete cytoreduction is the key to
maximizing survival outcomes after CS and HIPEC
for colorectal carcinomatosis. Additionally the ﬁnding
of an absolute increase in survival associated with
MVR (32.8 versus 20.2 months, P = 0.787) is
intriguing (despite this diﬀerence lacking statistical
signiﬁcance), perhaps reﬂecting a more complete cy-
toreduction inMVRpatients. A recent pooled analysis
from 28 centers, which included 506 patients who had
CS and PIC, demonstrated that completeness of cy-
toreduction was the principal prognostic variable in a
multivariate Cox regression model. Median survival
rates were as high as 32.4 months following complete
cytoreduction (no macroscopic residual carcinomato-
sis), 24 months followingnear-complete cytoreduction
(residual carcinomatosis nodules <5 mm), and only
8.4 months following incomplete reduction (residual
carcinomatosis nodules >5 mm) (P< 0.0001).7 In a
separate randomized comparison of CS and HIPEC
followed by systemic chemotherapy versus systemic
chemotherapy and supportive surgery alone, median
overall survival rate with complete resection has been
reported to be as high as 48 months versus less than
10 months when gross disease remained.3
There is also evidence that complete cytoreduction
(without PIC) in conjunction with systemic chemo-
therapy may confer a measurable beneﬁt for patients
with colorectal peritoneal metastases. A randomized
trial compared cytoreductive surgery with early PIC
followed by systemic chemotherapy versus CS fol-
lowed by systemic chemotherapy alone. Unfortu-
nately, due to strong patient preferences, this trial
closed prematurely after enrolling only 35 of a total
90 planned patients. An unexpected but very impor-
tant ﬁnding was the outstanding survival rate of 60%
at 2 years for either arm of the trial. Equally as
important was the observation that the PIC arm
experienced a higher rate of perioperative morbidity
and mortality that likely would have been statistically
signiﬁcant if the trial were to have completed its ac-
crual (69% versus 37%, P = 0.092). In addition,
fewer patients in the PIC arm subsequently received
postoperative systemic chemotherapy as scheduled
(56% versus 100%, P = 0.0017), perhaps as a result
of increased rates of morbidity and mortality.1
Although the beneﬁt of complete cytoreduction is
well demonstrated, the added beneﬁt of intraperito-
neal chemotherapy is not as clearly deﬁned. An
analysis of the distribution, timing, and outcomes of
recurrent disease after complete or near-complete
cytoreduction and PIC for peritoneal carcinomatosis
from colorectal cancer was recently reported.11 This
analysis included 70 patients with adequate cytore-
duction (deﬁned as <2.5 mm) out of a carefully
selected 156 attempted CS (58%). Despite optimal
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patient selection and aggressive CS, 49 patients
(78%) developed disease recurrence at a median time
of 9 months. In 21 patients (43%) disease recurrence
included distant metastases. Such high rates of
treatment failure (including distant metastases) de-
spite careful patient selection and complete CS with
HIPEC are the background against which the high
rates of morbidity and relatively short life expectancy
of patients with colorectal carcinomatosis must be
viewed. We must consider these and other potential
consequences of HIPEC (prolonged hospital stays,
increased length of time to complete recovery, and
decreased perioperative quality of life) in order to
make an evidenced-based recommendation regarding
its use.12 Furthermore, recent data reporting median
survival rates of up to 31.8 months among patients
with unresectable stage IV colorectal cancers receiv-
ing a maintenance regimen of the targeted anti-vas-
cular endothelial growth factor (VEGF) antibody,
bevacizumab, in combination with chemotherapy
make it imperative to determine the independent roles
of both CS and HIPEC in the context of the
continual evolution of more efﬁcacious systemic
therapy.13
Yet perhaps in these data are the hidden oppor-
tunities for the treatment of peritoneal carcinomato-
sis of colorectal origin. This study by Franko et al.
provides additional support of the rationale for sys-
tematic investigation of the independent roles of CS
and HIPEC in the context of modern systemic ther-
apy. Improvement in our understanding of the peri-
toneum as a resectable organ combined with
advanced intraperitoneal cytoreductive techniques
may now allow us to approach carcinomatosis as any
other site of resectable visceral metastasis. In addi-
tion, the improved eﬃcacy of systemic chemotherapy
oﬀers a potential opportunity to employ cytoreduc-
tive surgery as a component of multimodality cura-
tive therapy. Proper patient selection, including
referral of patients with peritoneal carcinomatosis
prior to exhaustion of systemic therapeutic options, is
essential. In determining the beneﬁt of CS alone,
without HIPEC, arises an opportunity to evaluate the
incremental beneﬁt of HIPEC. Determining the po-
tential beneﬁt of complete cytoreduction as an adju-
vant to best systemic therapy is both the rational and
essential next step.
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